Bcm Families Foundation is ranked among disease & disorders organizations in Jupiter, FL, with an America's Best Score of 69 out of 100, based on its 2025 Form 990.
Bcm Families Foundation is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G41). Contributions are tax-deductible.
Po Box 7711, Jupiter, FL 33468-7711
Among the 3 scored disease & disorders organizations in Jupiter, Bcm Families Foundation holds 16.5 months of operating reserves (peer median 19 months), runs a typical yearly surplus of 71.6% (peers: surplus of 71.6%), and has grown spending 19.5% a year (peers: grown spending 14.5% a year).
In fiscal year 2025 it reported $173,939 in revenue and $98,845 in expenses, with contributions making up 100.0% of revenue.
To provide financial support for research, projects, activities and organizations related to the diagnosis, treatment or cure of blue cone monochromacy (bcm). Also to establish networks and synergies with other groups and organizations dedicated to eye and/or other rare disease issues and to educate the general public regarding bcm.
Main program · fiscal year 2023
In 2023 the BCMFF worked in agreement with the Strategic Plan, in multiple directions-- Cure for BCM: After our biotech partner decided to stop the development of the BCM Gene Therapy in 2022, then in 2023 we decided to continue developments by financing some important parts by ourselves. In the meantime, the director John Cavitt resigned with the aim of implementing a fundraising program for the… Read more
In 2023 the BCMFF worked in agreement with the Strategic Plan, in multiple directions-- Cure for BCM: After our biotech partner decided to stop the development of the BCM Gene Therapy in 2022, then in 2023 we decided to continue developments by financing some important parts by ourselves. In the meantime, the director John Cavitt resigned with the aim of implementing a fundraising program for the treatment, founding the BlueGen Therapy Foundation, with which we started a constructive dialogue. One of the most important projects for the BCMFF in 2023 was to finance the University of Pennsylvania, where doctors Artur Cideciyan and Tomas Aleman worked in 2023 and until June 2024 on the clinical protocol and outcome measures of the gene therapy. The initial project cost was $148,759 of which $99,172 paid in 2023. In 2024 University of Pennsylvania requested $35,000 more to end the project and to coordinate with the European clinical center of Tubingen. BCMFF agreed. In 2023 the BCMFF financed also the study of Dr. Wentao Deng at the West Virginia University to test some intravitreal vectors received from the University of California Berkeley. The cost of the WVU project is $130,888; in 2023 we paid $100,000. Moreover, we paid $2,000 to UCB to have exclusive right to evaluate for 1 year an intravitreal vectors we received. There are some legal expenses related to close and discuss agreements of all these projects. Diagnosis The BCMFF started a collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland. We financed the Opsin Miner project of Dr. Mathieu Quinodoz for $8,784. This project can improve DNA tests and can be implemented in labs that perform Next Generation Sequencing DNA Tests. Patient preparation for Clinical Trial: We maintained and developed the BCM Patient Registry, a strategic project for the clinical trial. We paid for annual cost for hosting (AWS); software maintenance Digital Video; Registry Manager Sara Cammarota; legal fees to the Data Protection Officer CMS; annual ethics review from WIRB. An increased number of patients, families and clinicians participating in the Registry has been experienced in 2023. Community building: A European families meeting was held on September 19, 2023 in Tubingen, hosted by the University of Tubingen and by the Germany Achromatopsia association. A national families meeting was held in Charlotte, NC, on April 29, 2023. There are costs related to these meetings, mainly for the Charlotte Meeting, including services for the children room, hotel room scholarships, printed materials, hotel rooms and travel reimbursement for scientists and hotel services for the conference, partially paid in advance in 2022. BCMFF Reputation: We maintained connections with other patient organizations and umbrella organizations, such as NORD, Eurordis, Orphanet, Fastercures, Foundation Fighting Blindness, Berkeley Forum for Collaborative Research , Italian Achromats Association. Directors participated in the FloRetina conference and in several roundtables and webinars of the Berkeley Forum. Fundraising: Thanks only to the work of volunteers, with no expenses, we organized the Giving: Tuesday Campaign and the the Monthly Donors campaign.
$329,794 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 91¢ went to programs, 9¢ to management and 0¢ to fundraising.
Programs $89,772
Management $9,073
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
91%
Meets
Compared with Jupiter peers
Measure
This organization
Peer median
Operating reserves
16.5 mo
19.0 mo
Typical margin
+71.6%
+71.6%
Spending growth
+19.5% / yr
+14.5% / yr
Debt load
0.2%
0.2%
Peers: the 3 Jupiter disease & disorders organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$173,939Fiscal year 2025
Expenses$98,845Fiscal year 2025
Total assets$136,096Fiscal year 2025
Total liabilities$333Fiscal year 2025
Fiscal year ending December2025
Revenue$173,939
Expenses$98,845
Net income$75,094
Net assets$135,763
Notable sources of revenue
Percent of total revenue
Contributions
$173,939
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$136,096
Total liabilities
$333
Net assets
$135,763
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$175,825
Expenses$105,173
Net income$70,652
Net assets$60,669
Notable sources of revenue
Percent of total revenue
Contributions
$175,825
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$114,252
Total liabilities
$53,583
Net assets
$60,669
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$156,105
Expenses$336,805
Net income−$180,700
Net assets−$9,983
Notable sources of revenue
Percent of total revenue
Contributions
$156,105
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$85,687
Total liabilities
$95,670
Net assets
−$9,983
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$170,126
Expenses$57,866
Net income$112,260
Net assets$170,861
Notable sources of revenue
Percent of total revenue
Contributions
$170,126
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$186,176
Total liabilities
$15,315
Net assets
$170,861
Compensation
Officers and key employees
$0
Share of expenses
0.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?